Key Points
- Kevin Wilson sold 1,912 shares of BioSyent on March 30 at an average price of C$11.15 for C$21,318.80, reducing his holding by 3.04% to 61,058 shares valued at C$680,796.70.
- BioSyent stock opened at C$14.64 and trades in a one-year range of C$9.20–C$15.80, with a market cap of C$168.32M, a PE of 18.70, and 50-day/200-day moving averages of C$14.57 and C$12.76.
- BioSyent is a Canadian specialty pharmaceutical company that develops and sells products including FeraMAX (iron therapies), Tibella (hormone replacement), Inofolic, RepaGyn and Gelclair for various women's health and mucosal care needs.
BioSyent Inc. (CVE:RX - Get Free Report) insider Kevin Wilson sold 1,912 shares of BioSyent stock in a transaction on Monday, March 30th. The stock was sold at an average price of C$11.15, for a total value of C$21,318.80. Following the completion of the sale, the insider directly owned 61,058 shares of the company's stock, valued at C$680,796.70. The trade was a 3.04% decrease in their position.
BioSyent Stock Down 0.4%
BioSyent stock opened at C$14.64 on Tuesday. BioSyent Inc. has a one year low of C$9.20 and a one year high of C$15.80. The stock has a fifty day moving average of C$14.57 and a 200 day moving average of C$12.76. The company has a debt-to-equity ratio of 2.03, a quick ratio of 6.91 and a current ratio of 5.51. The stock has a market cap of C$168.32 million, a PE ratio of 18.70 and a beta of 0.93.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
